Mo1225 Population Pharmacokinetic Modeling of Vedolizumab in Patients With Ulcerative Colitis or Crohn's Disease
Nathanael L. Dirks(Metrum Research Group (United States)), Ashley Milton(Takeda (United States)), Irving H. Fox(Takeda (United States)), Marc R. Gastonguay(Metrum Research Group (United States)), Maria Rosario(Millennium Engineering and Integration (United States))
Cited by 3
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
|Gastroenterology|2014|714
Treatment of Ulcerative Colitis with a Humanized Antibody to the α <sub>4</sub> β <sub>7</sub> Integrin
|New England Journal of Medicine|2005|694